(Total Views: 1014)
Posted On: 12/17/2020 10:28:06 PM
Post# of 155130
I expect more movement into Cytodyn and Humanigen after the failure of Mesoblast.
Nonetheless, I'm still amazed at the support for Humanigen after the lengthening of their trial, endpoint change from intubation or death to time to recovery and their extensive exclusion list:
Requiring invasive mechanical ventilation or extracorporeal membrane oxygenation prior to randomization
Confirmed diagnosis of bacterial pneumonia or other active/uncontrolled fungal or viral infections at screening/baseline
Known active tuberculosis (TB), history of incompletely treated TB or suspected or known extrapulmonary TB
Currently receiving treatment for hepatitis A, hepatitis B, hepatitis C or HIV infection
I would feel sorry for those choosing Humanigen over Cytodyn, but there are abundant available resources validating leronlimab, even in advance of CD12 readout.
Lots of fun to be had when 20 or 30 billion dollars chase Cytodyn stock.
Nonetheless, I'm still amazed at the support for Humanigen after the lengthening of their trial, endpoint change from intubation or death to time to recovery and their extensive exclusion list:
Requiring invasive mechanical ventilation or extracorporeal membrane oxygenation prior to randomization
Confirmed diagnosis of bacterial pneumonia or other active/uncontrolled fungal or viral infections at screening/baseline
Known active tuberculosis (TB), history of incompletely treated TB or suspected or known extrapulmonary TB
Currently receiving treatment for hepatitis A, hepatitis B, hepatitis C or HIV infection
I would feel sorry for those choosing Humanigen over Cytodyn, but there are abundant available resources validating leronlimab, even in advance of CD12 readout.
Lots of fun to be had when 20 or 30 billion dollars chase Cytodyn stock.
(6)
(0)
